These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12063551)

  • 1. GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
    Agrawal S; Kandimalla ER; Yu D; Ball R; Lombardi G; Lucas T; Dexter DL; Hollister BA; Chen SF
    Int J Oncol; 2002 Jul; 21(1):65-72. PubMed ID: 12063551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.
    Wang H; Hang J; Shi Z; Li M; Yu D; Kandimalla ER; Agrawal S; Zhang R
    Int J Oncol; 2002 Jul; 21(1):73-80. PubMed ID: 12063552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
    Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
    Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
    Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.
    Agrawal S; Kandimalla ER; Yu D; Hollister BA; Chen SF; Dexter DL; Alford TL; Hill B; Bailey KS; Bono CP; Knoerzer DL; Morton PA
    Int J Oncol; 2001 May; 18(5):1061-9. PubMed ID: 11295057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
    Cho YS; Cho-Chung YS
    Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.
    Wang H; Cai Q; Zeng X; Yu D; Agrawal S; Zhang R
    Proc Natl Acad Sci U S A; 1999 Nov; 96(24):13989-94. PubMed ID: 10570186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
    Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ
    Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production.
    Tortora G; Bianco R; Damiano V; Fontanini G; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2000 Jun; 6(6):2506-12. PubMed ID: 10873106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIalpha protein.
    Nesterova M; Noguchi K; Park YG; Lee YN; Cho-Chung YS
    Clin Cancer Res; 2000 Sep; 6(9):3434-41. PubMed ID: 10999726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
    Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
    Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor activity of capecitabine in combination with irinotecan.
    Cao S; Durrani FA; Rustum YM
    Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
    Cao S; Durrani FA; Rustum YM
    Clin Cancer Res; 2004 Apr; 10(7):2561-9. PubMed ID: 15073137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
    Tortora G; Caputo R; Damiano V; Bianco R; Fontanini G; Cuccato S; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
    Ravi R; Jain AJ; Schulick RD; Pham V; Prouser TS; Allen H; Mayer EG; Yu H; Pardoll DM; Ashkenazi A; Bedi A
    Cancer Res; 2004 Dec; 64(24):9105-14. PubMed ID: 15604280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I.
    Mani S; Goel S; Nesterova M; Martin RM; Grindel JM; Rothenberg ML; Zhang R; Tortora G; Cho-Chung YS
    Ann N Y Acad Sci; 2003 Dec; 1002():252-62. PubMed ID: 14751840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PKA knockdown enhances cell killing in response to radiation and androgen deprivation.
    Hensley HH; Hannoun-Levi JM; Hachem P; Mu Z; Stoyanova R; Khor LY; Agrawal S; Pollack A
    Int J Cancer; 2011 Feb; 128(4):962-73. PubMed ID: 20960462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
    Sabatino MA; Colombo T; Geroni C; Marchini S; Broggini M
    Clin Cancer Res; 2003 Nov; 9(14):5402-8. PubMed ID: 14614026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.